Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: The HEmochromatosis FAmily Study (HEFAS)

Netherlands Journal of Medicine

Volumn 65, Issue 11, 2007, Pages 425-433

  Jacobs, E M G ^a   Hendriks, J C M ^a   Marx, J J M ^a,b   van Deursen, C Th B M ^c   Kreeftenberg, H G ^d   de Vries, R A ^e   Stalenhoef, A F H ^a   Verbeek, A L M ^a   Swinkels, D W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Family; Hereditary haemochromatosis; HFE; Morality; Morbidity

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIRHEUMATIC AGENT; CARDIOVASCULAR AGENT; DIURETIC AGENT; FERRITIN; MOLECULAR MARKER; TRANSFERRIN;

ADULT; AGE DISTRIBUTION; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY STUDY; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GENETIC SCREENING; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OSTEOPOROSIS; QUESTIONNAIRE; RHEUMATIC DISEASE; SELF REPORT; SEX RATIO; TRANSFERRIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NETHERLANDS; PREVALENCE; QUESTIONNAIRES; RISK FACTORS;

EID: 38049011311     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
2. McDonnell SM, Preston BL, Jewell SA, et al. A survey Of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
3. Powell LW, Dixon JL, Ramm et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-301.
4. Milman N, Pedersen P, Steig T, et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001;80:737-44.
5. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:11O7-19.
6. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976;45:611-23.
7. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001;154:193-206.
8. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance Of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
9. Andersen RV, Tybjaerg-Hansen A, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-9.
10. Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2007;36:1108-75.
11. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
12. Krawczak M, Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001;69:361-70.
13. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO 1968.
14. Hoogendoorn EH, Hermus AR, de Vegt F, et al. Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem 2006;52:104-11.
15. Sindram JW, Marx JJ. Localisation of iron in the hepatic acini and in bile duct epithelium as a tool for estimation of liver iron overload. Ann N Y Acad Sci 1988;526:361-2.
16. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
17. Alberts M, Vercoulen JHMM, Bleijenberg G. Assessment of fatigue - the practical utility ofthe subjective feeling of fatigue in research and clinical practice. Assessment in Behavioral Medicine. Brunner-Routledge, 2001, PP 301-27.
18. Coppin H, Bensaid M, Fruchon S, et al. Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene: case control study of 492 French centenarians. BMJ 2003;327:132-3.
19. Piippo K, Louhija J, Tilvis R, et al. You may live to the age of more than 100 years even if you are homozygous for a haemochromatosis gene mutation. Eur J Clin Invest 2003;33:830-31.
20. Van Aken MO, De Craen AJ, Gussekloo et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-Plus study. Eur J Clin Invest 2002;32:750-4.
21. Willis G, Wimperis JZ, Smith KC, et al. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 1999;354:221-2.
22. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
23. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology 1995;22:1720-7.
24. Gleeson F, Ryan E, Barrett S, et al. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol 2004;16:859-63.
25. McCune CA, Ravine D, Carter K, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006;55:554-62.
26. Rochette J, Pointon JJ, Fisher CA, Perera G, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999;64:1056-62.
27. Moalem S, Percy ME, Kruck TP, et al. Epidemic pathogenic selection: an explanation for hereditary hemochromatosis? Med Hypotheses 2002;59:325-9.
28. De Almeida SF, Carvalho IF, Cardoso CS, et al. HFE crosstalks with the MHC class I antigen presentation pathway. Blood 2005;106:971-7.
29. Cardoso CS, de Sousa M. HFE, the MHC and hemochromatosis: paradigm for an extended function for MHC class I. Tissue Antigens 2003;61:263-75.
30. Kartikasari AE, Georgiou NA, Visseren FL, et al. Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J 2006;20:353-5.
31. Butterworth JR, Cooper BT, Rosenberg WM et al. The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology 2002;123:444-9.